Concordia Healthcare Corp. (NASDAQ:CXRX) (TSE:CXR)‘s stock had its “sector perform” rating reiterated by research analysts at RBC Capital Markets in a report released on Wednesday.

A number of other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Concordia Healthcare Corp. from a “hold” rating to a “strong sell” rating in a research note on Friday, November 11th. Bloom Burton cut shares of Concordia Healthcare Corp. from a “hold” rating to a “sell” rating in a research note on Monday, November 7th. Canaccord Genuity cut shares of Concordia Healthcare Corp. from a “hold” rating to a “sell” rating in a research note on Monday, November 7th. Scotiabank restated a “sector perform” rating and set a $4.50 price target (down previously from $8.00) on shares of Concordia Healthcare Corp. in a research note on Wednesday, October 12th. Finally, Goldman Sachs Group Inc. restated a “neutral” rating on shares of Concordia Healthcare Corp. in a research note on Tuesday, September 27th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $28.53.

Analyst Recommendations for Concordia Healthcare Corp. (NASDAQ:CXRX)

Concordia Healthcare Corp. (NASDAQ:CXRX) traded up 3.19% during trading on Wednesday, hitting $2.59. The stock had a trading volume of 731,250 shares. The company’s market cap is $132.13 million. The stock has a 50-day moving average price of $3.40 and a 200-day moving average price of $13.56. Concordia Healthcare Corp. has a 52 week low of $1.69 and a 52 week high of $44.00.

Concordia Healthcare Corp. (NASDAQ:CXRX) last issued its quarterly earnings results on Monday, November 7th. The company reported $0.69 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.05 by $0.36. The business earned $185.50 million during the quarter, compared to analyst estimates of $206 million. Concordia Healthcare Corp. had a negative net margin of 81.40% and a positive return on equity of 22.81%. The company’s revenue for the quarter was up 99.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.46 earnings per share. Equities analysts predict that Concordia Healthcare Corp. will post $4.19 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Concordia Healthcare Corp.’s (CXRX) “Sector Perform” Rating Reaffirmed at RBC Capital Markets” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of US and international trademark & copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/concordia-healthcare-corp-s-cxrx-sector-perform-rating-reaffirmed-at-rbc-capital-markets.html.

Several institutional investors have recently made changes to their positions in CXRX. ProShare Advisors LLC boosted its position in shares of Concordia Healthcare Corp. by 0.6% in the second quarter. ProShare Advisors LLC now owns 37,975 shares of the company’s stock worth $818,000 after buying an additional 224 shares in the last quarter. Citigroup Inc. boosted its position in shares of Concordia Healthcare Corp. by 18.5% in the second quarter. Citigroup Inc. now owns 8,976 shares of the company’s stock worth $184,000 after buying an additional 1,401 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Concordia Healthcare Corp. by 15.5% in the first quarter. Goldman Sachs Group Inc. now owns 79,981 shares of the company’s stock worth $2,047,000 after buying an additional 10,734 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Concordia Healthcare Corp. by 64.3% in the second quarter. UBS Asset Management Americas Inc. now owns 27,859 shares of the company’s stock worth $597,000 after buying an additional 10,900 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Concordia Healthcare Corp. during the second quarter worth $309,000. 36.96% of the stock is currently owned by institutional investors.

Concordia Healthcare Corp. Company Profile

5 Day Chart for NASDAQ:CXRX

Receive News & Stock Ratings for Concordia Healthcare Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp. and related stocks with our FREE daily email newsletter.